Manidipine Viatris (Manidipine Dihydrochloride)

Manidipine is a dihydropyridine calcium‑channel blocker indicated for the management of high blood pressure.

• Essential hypertension: reduces systolic and diastolic pressure by relaxing peripheral arteries.
• Isolated systolic hypertension: lowers elevated systolic readings while maintaining diastolic stability.
• Renal hypertension: improves renal perfusion pressure by decreasing systemic vascular resistance.

• Manidipine selectively blocks L‑type calcium channels on vascular smooth muscle, inhibiting calcium influx that is necessary for contraction. This antagonism causes dose‑dependent peripheral vasodilation, decreasing systemic vascular resistance and consequently lowering arterial blood pressure without significant negative inotropic effects on the heart.

Manidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warm sensation, usually resolves with continued therapy.
• Peripheral edema: swelling of ankles or lower legs.
• Dizziness or light‑headedness, especially after standing.
• Nausea or abdominal discomfort.
• Tachycardia: increased heart rate without other cardiac symptoms.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angioedema: swelling of face, lips, tongue, or throat.
• Myocardial infarction: chest pain or discomfort suggestive of heart attack.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Arrhythmias: irregular heart rhythms requiring monitoring.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects.
• Cardiovascular disease: monitor for signs of ischemia or heart failure.
• Sudden discontinuation: taper gradually to prevent rebound hypertension.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Manidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• Other calcium‑channel blockers: additive vasodilatory effect leading to severe hypotension.
• Potent antihypertensives (e.g., ACE inhibitors, ARBs): risk of excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.

• NSAIDs: can blunt antihypertensive response.
• Diuretics: may enhance orthostatic hypotension.
• Beta‑blockers: monitor heart rate and blood pressure.
• Grapefruit juice: may modestly increase drug exposure.